Literature DB >> 28438346

Post-bronchodilator Reversibility of FEV1 and Eosinophilic Airway Inflammation in COPD.

Kun-Ta Chou1, Kang-Cheng Su2, Yi-Han Hsiao3, Shiang-Fen Huang3, Hsin-Kuo Ko3, Ching-Min Tseng3, Vincent Yi-Fong Su3, Diahn-Warng Perng4.   

Abstract

INTRODUCTION: The relationship between bronchodilator responsiveness and eosinophilic airway inflammation has not been well documented in COPD. It has been investigated in this retrospective study. This issue has grown in importance due to increasing interest in the asthma-COPD overlap syndrome.
METHODS: 264 stable COPD patients with no past history of asthma were retrospectively analyzed. Correlation analyses between FEV1 reversibility and sputum eosinophil levels were conducted. Sputum eosinophil levels were dichotomized using FEV1 reversibility cut-off points (>0.4L and >15% vs. >0.2L and >12%) and compared. The effectiveness of FEV1 reversibility to predict sputum eosinophilia (>3%) was analyzed with a logistic regression and a ROC analysis.
RESULTS: 82 (31.1%) patients with higher FEV1 reversibility values (0.14 vs. 0.11L, P=.01) presented sputum eosinophilia. FEV1 reversibility was weakly correlated with the sputum eosinophil level (r=0.162, P=.008). Patients with FEV1>0.4L and >15% increment had higher sputum eosinophil levels (6.11 vs. 1.02%, P=.049) whereas the level did not differ when dichotomized by FEV1 increment >0.2L and >12%. Very positive FEV1 reversibility (>0.4L and >15%) predicted sputum eosinophilia after adjustment forage, baseline FEV1 and FVC (OR: 4.262, P=.029). In the ROC analysis, the AUC was 0.58 (P=.034), and FEV1 increment>0.4L and >15% had a positive predictive value of 63.6% and an overall accuracy of 70.1%.
CONCLUSIONS: FEV1 reversibility was weakly correlated with sputum eosinophil levels in COPD. Positive FEV1 reversibility (>0.4L and >15%) is moderately successful in predicting sputum eosinophilia (>3%).
Copyright © 2017 SEPAR. Publicado por Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Asthma-COPD overlap syndrome; Bronchodilator test; COPD; EPOC; Eosinophil; Eosinófilo; FEV(1) reversibility; Fenotipo mixto asma-EPOC; Prueba broncodilatadora; Reversibilidad del FEV(1)

Mesh:

Substances:

Year:  2017        PMID: 28438346     DOI: 10.1016/j.arbres.2017.01.014

Source DB:  PubMed          Journal:  Arch Bronconeumol        ISSN: 0300-2896            Impact factor:   4.872


  4 in total

1.  Clinical value of IL-13 and ECP in the serum and sputum of eosinophilic AECOPD patients.

Authors:  Ting Li; Li Gao; Hong-Xia Ma; Yang-Yang Wei; Yue-Hua Liu; Ke-Ru Qin; Wen-Tao Wang; Hai-Long Wang; Min Pang
Journal:  Exp Biol Med (Maywood)       Date:  2020-06-03

Review 2.  The Relationship between Airway Inflammation and Exacerbation in Chronic Obstructive Pulmonary Disease.

Authors:  Diahn Warng Perng; Pei Ku Chen
Journal:  Tuberc Respir Dis (Seoul)       Date:  2017-09-04

3.  Predictors of asthma-chronic obstructive pulmonary disease overlap syndrome in patients with chronic obstructive pulmonary disease from a tertiary care center in India.

Authors:  Irfan Ismail Ayub; Abdul Majeed Arshad; Prathipa Sekar; Natraj Manimaran; Dhanasekar Thangaswamy; Chandrasekar Chockalingam
Journal:  Lung India       Date:  2018 Mar-Apr

4.  Eicosanoids and Eosinophilic Inflammation of Airways in Stable COPD.

Authors:  Natalia Celejewska-Wójcik; Aleksander Kania; Karolina Górka; Paweł Nastałek; Krzysztof Wójcik; Anna Gielicz; Lucyna Mastalerz; Marek Sanak; Krzysztof Sładek
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-05-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.